Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Maribavir versus investigator-assigned anti-CMV therapy in transplant recipients with refractory or resistant CMV infection
2015-004725-13Phase 3Completed
- Sponsor
- Takeda
- Start
- Dec 2016
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of maribavir in cytomegalovirus disease (CMV) and Refractory cytomegalovirus infection (R-CMV) (2 arms), sponsored by Takeda. Primary endpoint: Confirmed CMV viremia clearance. Started Dec 2016; status: completed.
02
Drugs
maribavir
03
Conditions
cytomegalovirus disease (CMV)Refractory cytomegalovirus infection (R-CMV)
Beyond the preview
Go deeper on 2015-004725-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-004725-13.